$429 Million is the total value of GREAT POINT PARTNERS LLC's 36 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 73.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| EXEL | Buy | EXELIXIS INC | $32,239,000 | +26.9% | 1,525,000 | +9.4% | 7.51% | +40.9% |
| ARNA | Buy | ARENA PHARMACEUTICALS INC | $31,601,000 | -8.4% | 530,670 | +4.9% | 7.36% | +1.7% |
| KDMN | Sell | KADMON HLDGS INC | $29,396,000 | +57.3% | 3,375,000 | -30.1% | 6.84% | +74.6% |
| BCAB | New | BIOATLA INC | $24,847,000 | – | 844,002 | +100.0% | 5.78% | – |
| RCKT | Sell | ROCKET PHARMACEUTICALS INC | $22,866,000 | -36.8% | 765,000 | -6.4% | 5.32% | -29.9% |
| MGNX | Sell | MACROGENICS INC | $20,940,000 | -43.4% | 1,000,000 | -27.5% | 4.88% | -37.2% |
| DRNA | New | DICERNA PHARMACEUTICALS INC | $16,128,000 | – | 799,999 | +100.0% | 3.76% | – |
| UTHR | Sell | UNITED THERAPEUTICS CORP DEL | $15,997,000 | -49.5% | 86,667 | -50.9% | 3.72% | -43.9% |
| VRTX | New | VERTEX PHARMACEUTICALS INC | $15,418,000 | – | 85,000 | +100.0% | 3.59% | – |
| TVTX | Sell | TRAVERE THERAPEUTICS INC | $15,156,000 | -4.2% | 625,000 | -42.4% | 3.53% | +6.3% |
| ANAB | Buy | ANAPTYSBIO INC | $14,904,000 | +43.7% | 549,545 | +37.4% | 3.47% | +59.5% |
| CYTK | New | CYTOKINETICS INC | $13,990,000 | – | 391,429 | +100.0% | 3.26% | – |
| BIIB | Buy | BIOGEN INC | $13,442,000 | +19.4% | 47,500 | +46.2% | 3.13% | +32.6% |
| URGN | New | UROGEN PHARMA LTD | $12,615,000 | – | 750,000 | +100.0% | 2.94% | – |
| DYN | Buy | DYNE THERAPEUTICS INC | $12,099,000 | -14.5% | 745,000 | +10.8% | 2.82% | -5.1% |
| SAGE | Buy | SAGE THERAPEUTICS INC | $11,920,000 | -16.1% | 269,010 | +7.6% | 2.78% | -6.8% |
| XENE | New | XENON PHARMACEUTICALS INC | $10,696,000 | – | 700,000 | +100.0% | 2.49% | – |
| TCDA | TRICIDA INC | $9,159,000 | +7.4% | 1,974,000 | 0.0% | 2.13% | +19.2% | |
| PBYI | PUMA BIOTECHNOLOGY INC | $9,113,000 | -23.6% | 1,300,000 | 0.0% | 2.12% | -15.2% | |
| OLMA | OLEMA PHARMACEUTICALS INC | $9,070,000 | -1.5% | 329,086 | 0.0% | 2.11% | +9.3% | |
| NKTR | New | NEKTAR THERAPEUTICS | $9,064,000 | – | 504,691 | +100.0% | 2.11% | – |
| ACRS | New | ACLARIS THERAPEUTICS INC | $9,000,000 | – | 500,000 | +100.0% | 2.10% | – |
| RFL | New | RAFAEL HLDGS INC | $8,780,000 | – | 285,714 | +100.0% | 2.04% | – |
| MGTA | Buy | MAGENTA THERAPEUTICS INC | $8,518,000 | -21.6% | 1,170,000 | +5.3% | 1.98% | -13.0% |
| CTMX | Buy | CYTOMX THERAPEUTICS INC | $7,635,000 | +20.6% | 1,500,000 | +50.0% | 1.78% | +33.9% |
| RIGL | Buy | RIGEL PHARMACEUTICALS INC | $7,187,000 | +10.4% | 1,980,000 | +32.0% | 1.67% | +22.5% |
| AGLE | AEGLEA BIOTHERAPEUTICS INC | $7,155,000 | +14.2% | 900,000 | 0.0% | 1.67% | +26.8% | |
| PHAT | New | PHATHOM PHARMACEUTICALS INC | $7,090,000 | – | 220,863 | +100.0% | 1.65% | – |
| APLS | New | APELLIS PHARMACEUTICALS INCcall | $6,592,000 | – | 200,000 | +100.0% | 1.54% | – |
| KNSA | New | KINIKSA PHARMACEUTICALS LTD | $5,467,000 | – | 480,000 | +100.0% | 1.27% | – |
| PCVX | New | VAXCYTE INC | $2,488,000 | – | 98,061 | +100.0% | 0.58% | – |
| RPTX | Sell | REPARE THERAPEUTICS INC | $2,444,000 | -82.0% | 93,137 | -78.6% | 0.57% | -80.0% |
| COLL | Sell | COLLEGIUM PHARMACEUTICAL INC | $2,395,000 | -88.2% | 121,342 | -85.9% | 0.56% | -86.9% |
| FOLD | Sell | AMICUS THERAPEUTICS INC | $2,378,000 | -84.6% | 249,000 | -84.4% | 0.55% | -82.9% |
| IFRX | Sell | INFLARX NV | $1,429,000 | -78.1% | 551,918 | -74.9% | 0.33% | -75.7% |
| PRQR | New | PROQR THRAPEUTICS N V | $254,000 | – | 30,336 | +100.0% | 0.06% | – |
| VERV | Exit | VERVE THERAPEUTICS INC | $0 | – | -35,000 | -100.0% | -0.44% | – |
| KURA | Exit | KURA ONCOLOGY INC | $0 | – | -500,000 | -100.0% | -2.19% | – |
| XENT | Exit | INTERSECT ENT INC | $0 | – | -700,000 | -100.0% | -2.51% | – |
| OCUL | Exit | OCULAR THERAPEUTIX INC | $0 | – | -919,887 | -100.0% | -2.74% | – |
| FGEN | Exit | FIBROGEN INCcall | $0 | – | -500,000 | -100.0% | -2.79% | – |
| MRTX | Exit | MIRATI THERAPEUTICS INC | $0 | – | -100,000 | -100.0% | -3.39% | – |
| NTLA | Exit | INTELLIA THERAPEUTICS INCcall | $0 | – | -100,000 | -100.0% | -3.40% | – |
| PODD | Exit | INSULET CORP | $0 | – | -104,600 | -100.0% | -6.02% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STREAMLINE HEALTH SOLUTNS, INC CMN | 25 | Q3 2019 | 2.5% |
| IOVANCE BIOTHERAPEUTICS, INC. CMN | 16 | Q1 2021 | 14.3% |
| ZOGENIX INC CMN | 16 | Q4 2019 | 8.8% |
| PTC THERAPEUTICS, INC. CMN | 16 | Q3 2023 | 9.9% |
| EXELIXIS, INC | 16 | Q1 2022 | 7.5% |
| SAGE THERAPEUTICS, INC CMN | 15 | Q3 2021 | 10.8% |
| CYTOKINETICS INC | 15 | Q3 2023 | 5.8% |
| ACADIA PHARMACEUTICALS, INC. | 14 | Q1 2021 | 8.8% |
| ACCELERON PHARMA INC CMN | 14 | Q2 2020 | 8.2% |
| CONNECTURE INC | 13 | Q4 2017 | 25.1% |
View GREAT POINT PARTNERS LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| 89bio, Inc. | February 14, 2023 | 700,000 | 1.4% |
| KalVista Pharmaceuticals, Inc. | February 14, 2023 | 1,055,801 | 3.1% |
| Avalo Therapeutics, Inc. | February 13, 2023 | 974,639 | 7.1% |
| InflaRx N.V.Sold out | February 14, 2022 | 0 | 0.0% |
| ABEONA THERAPEUTICS INC.Sold out | February 16, 2021 | 0 | 0.0% |
| CONSTELLATION PHARMACEUTICALS INC | February 16, 2021 | 1,024,800 | 2.2% |
| GERON CORP | February 16, 2021 | 12,754,228 | 4.0% |
| Millendo Therapeutics, Inc. | February 16, 2021 | 270,000 | 1.4% |
| NextCure, Inc.Sold out | February 16, 2021 | 0 | 0.0% |
| PROTHENA CORP PUBLIC LTD CO | February 16, 2021 | 977,647 | 2.4% |
View GREAT POINT PARTNERS LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View GREAT POINT PARTNERS LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.